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ABSTRACT 
Biotène
®
 products have been developed with the intention of preventing tooth decay, plaque 
accumulation and oral infections in individuals with xerostomia (dry mouth). Not much is 
known about the effect of Biotène
®
 chewing gums. Biotène
®
 chewing gum contains host 
proteins. Due to these contents the manufacturer claims that Biotène
®
 chewing gum is an 
“enzyme gum” that “boosts and strengthens the mouths natural defences”. The aim of this 
study was to investigate the effect of Biotène
®
 chewing gum on saliva flow rates, saliva 
buffering capacity, plaque index, as well as salivary Streptococcus mutans and Lactobacilli 
counts, in healthy subjects with hyposalivation.  
One hundred and nine subjects with an age range of 18 to 23 years were screened for 
hyposalivation. Hyposalivation is a reduced salivary flow rate in a subject based on 
examination of the subject. Thirteen healthy subjects, who initially presented with 
hyposalivation, were included in the study. A baseline laboratory analysis of saliva was 
performed. Saliva was collected at rest and with masticatory stimulation, and measured. 
Resting saliva is saliva produced without any stimulation and can be obtained by allowing the 
subject to passively drool into a sputum jar. Stimulated saliva is produced as a result of 
stimulation of the salivary glands and may be obtained by allowing subject to chew inert 
rubber tubing while expectorating into a sputum jar. Buffering capacity was performed on 
both the saliva samples. Plaque index and DMFT was measured. Bacterial counts such as S. 
mutans and Lactobacilli counts were performed on the stimulated saliva.  
Subjects were given rubber tubing, xylitol chewing gum or Biotène
®
 chewing gum to use for 
2 weeks. A rubber tubing phase was introduced into the study to eliminate the effect of 
masticatory stimulation, which any chewing gum can provide. A xylitol-containing chewing 
gum (xylitol) phase was also introduced into the study in order to eliminate the effect of 
xylitol, as Biotène
®
 chewing gum contains xylitol.  
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A second laboratory analysis of saliva was performed. After a two weeks wash out period the 
second test product was given and the same procedure was repeated with the third product. 
The results showed that two weeks use of Biotène
®
 chewing gum had no significant effect on 
the resting and stimulated saliva flows. It did not increase the buffering capacity of either the 
resting or stimulated saliva samples. Although it did not reduce the plaque index and S. 
mutans counts, it significantly reduced the Lactobacilli counts.  Xylitol chewing gum, which 
was used as a control to eliminate the xylitol effect from the Biotène
®
 chewing gum, 
significantly increased the stimulated saliva, reduced the plaque index and the salivary 
Lactobacilli count. Biotène
®
 chewing gum which contains host proteins has no beneficial 
effects regarding saliva flow rate or against dental plaque and therefore against dental caries. 
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PREFACE 
 
Many studies have investigated the effects of Biotène
®
 products on hyposalivation. However 
not much is known about the effect of Biotène
®
 chewing gums alone. Thus the purpose of 
this study was to investigate the effect of Biotène
® 
chewing gum, which contains host 
proteins, on certain salivary parameters. The results of this study will establish whether 
Biotène
®
 chewing gum improves certain salivary parameters which are responsible for the 
development of dental caries in hyposalivators.  
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1        INTRODUCTION AND LITERATURE REVIEW   
1.1   INTRODUCTION 
Saliva has many important functions in the oral cavity. Lack of saliva results in xerostomia 
(dry mouth) which may become extremely debilitating for patients as it leads to difficulties in 
speech, swallowing and taste. Lack of saliva may result in increased susceptibility to dental 
caries as saliva has many functions which prevent dental caries. These include its mechanical 
washing action, buffering capacity and antimicrobial functions. Xerostomia may be a result 
of certain medications, systemic conditions, cancer therapy to the head and neck regions, or 
dehydration. But xerostomia or hyposalivation may also affect normal, healthy individuals.
1, 2
  
 Salivary stimulants and salivary substitutes are commonly used for the treatment of 
xerostomia. Chewing gum offers masticatory as well as gustatory stimulation of the salivary 
glands. Biotène
®
 products have been developed with the intention of supplementing the 
natural saliva with enzymes and proteins. This chewing gum contains lactoperoxidase and 
glucose oxidase as well as natural sugar alcohols, including xylitol according to the 
manufacturers packaging.  No studies have focused specifically on Biotène
®
 chewing gum. 
This study was undertaken in order to investigate the effect of Biotène
®
 chewing gum on 
saliva flow rate, buffering capacity of saliva, plaque index and salivary levels of 
Streptococcus mutans and Lactobacilli, in healthy subjects with hyposalivation. 
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1.2   LITERATURE REVIEW 
1.2.1 Saliva 
Saliva is primarily composed of water, proteins and electrolytes.
3 
It plays an important role in 
lubrication of the oral cavity, speech, swallowing and taste. Saliva contains mucin, which 
aids in the production of the food bolus, as well as lingual lipase and amylase which initiates 
the breakdown of fats and carbohydrates respectively. The mechanical washing action of 
saliva is important in removing food debris and unattached oral microorganisms. Saliva has a 
high buffering capacity which neutralises acids produced by bacteria on tooth surfaces. It is 
supersaturated with phosphate and calcium ions that aid in the remineralisation of teeth, as 
well as potassium bicarbonate which aids in the creation of a neutral pH. In addition it has 
advanced antimicrobial functions as it contains immunoglobulin A, histatins, lysozyme, 
lactoperoxidase, lactoferrin, agglutinins and defensins.  Lysozymes hydrolyse the bacterial 
cell wall polysaccharides, which results in lysis of the cell. The lactoperoxidase system 
protects mucosal cells from the toxicity of hydrogen peroxide which is produced by oral 
bacteria.
4 
Lactoferrin is an iron-binding glycoprotein which exhibits bacteriostatic and 
bactericidal activity against oral bacteria.
5
  
Dental caries is an irreversible, infectious disease of the teeth which is characterised by 
demineralisation of the inorganic portion and destruction of the organic portion of the tooth 
which eventually leads to cavity formation.
6
 It is a multifactorial disease which is dependent 
on a susceptible host, a host with a diet that is rich in fermentable carbohydrates, the presence 
of cariogenic bacteria and extended periods of time in which plaque is in contact with tooth 
surfaces. Risk factors for dental caries include poor oral hygiene, high levels of cariogenic 
bacteria, low fluoride levels in the water, low saliva flow rates and frequent exposure to 
fermentable carbohydrates. 
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Dental plaque is a colonisation of endogenous microorganisms on the tooth surface that 
causes tooth dissolution.
7
 Endogenous micro-organisms which are capable of adhering to the 
salivary pellicle which has formed on the tooth surface, adhere to the tooth surface via the 
pellicle and also aid in the subsequent aggregation of other micro-organisms that were not 
capable of initial aggregation. Micro-organisms found in dental plaque include Streptococci, 
Staphylococcus, Actinomyces, Veillonella, Propionibact, Prevotella, Neisseria, Lactobacilli, 
Fusobact and Rothia. 
S. mutans bind to the tooth pellicle via adhesins. The S. mutans then secrete glucosyl 
transferases which aid in the accumulation of more S. mutans. S. mutans are one of the initial 
colonisers of the tooth pellicle but they initially only comprise 1% of the colonising 
population.
8
 S. mutans then metabolises fermentable carbohydrates and releases lactic acid 
which causes enamel demineralisation. Furthermore, this acidic environment causes aciduric 
organisms such as S. mutans and Lactobacilli to flourish. S. mutans are implicated in dental 
caries as S. mutans are aciduric and acidogenic, they rapidly metabolise sugar and there is a 
correlation between salivary counts of S. mutans and the prevelance of caries. Lactobacilli are 
implicated in dental caries as they are also aciduric and acidogenic, they are high in numbers 
in most carious lesions, their numbers in plaque and saliva increase with an increase in caries 
activity and they produce lactic acid below a pH of 5.0. 
The oral fluids buffer the plaque on the tooth within 30-60 minutes with phosphates and 
bicarbonates. This results in remineralisation of the tooth enamel. However if there are 
repeated fluctuations in the pH and if the acid production outweighs the buffering effect of 
the saliva, the aciduric micro-organisms are allowed to multiply, produce even more acid and 
cause sufficient tooth demineralisation that will result in a dental cavity. Thus saliva is 
important in prevention of dental caries as a decrease in saliva allows cariogenic 
microorganisms to flourish.  
17 
 
A decrease in saliva may also result in difficulties with speaking, chewing, swallowing and 
tasting. Furthermore patients with hyposalivation may present with increased risk of dental 
caries 
9
, oral candidiasis
10
, periodontal disease and poor retention of dentures.
11
 
1.2.2 Xerostomia 
Xerostomia can be defined as “a subjective sensation of a dry mouth that is frequently, but 
not always, associated with salivary gland hypofunction”.12 Symptoms of xerostomia start 
when there is a decrease of 45% in normal salivary flow.
13 
A patient is considered to have 
reduced salivary flow if the unstimulated salivary flow is <0.1 ml/min measured for 5 to 15 
minutes or if the chewing-stimulated salivary flow is < 0.7 ml/min measured for 5 minutes.
14 
 
1.2.2.1 Xerostomia and gender 
Several studies have shown that xerostomia is more commonly found amongst females.            
A study conducted by Nederfors et al (1997) using a questionnaire on 4200 randomly 
selected individuals aged 20-80 years, found a prevalence of xerostomia in 21.3% of men and 
27.3% of women.
15 
Billings et al (1996) administered an oral health questionnaire and oral 
examination on 710 American adults with ages ranging from 19-88 years. Eighteen percent of 
males and 24% of females from this sample suffered from xerostomia.
16 
Similarly a study in 
Sweden also showed 15% of men and 22% of women had an unstimulated saliva flow below 
0.1ml/min.
2
  
1.2.2.2 Xerostomia and medication 
Xerostomia may be caused most frequently by dehydration, certain medications, diseases of 
the salivary glands, anxiety and radiation therapy to the head and neck. Ionising radiation can 
cause atrophy of the secretory components of both major and minor salivary glands resulting 
in xerostomia.
17 
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There are certain drugs that may be commonly associated with xerostomia. These drugs 
include bronchodilators, antiparkinsonian drugs, tricyclic antidepressants, antipsychotics, 
decongestants, antihistamines, mydriatic eye drops, antihypertensives, drugs for urinary 
incontinence, drugs for irritable bowel and diverticular diseases, cytotoxics, antiepileptics and 
diuretics.
18, 19 
People on xerogenic drugs produce significantly lower unstimulated and 
stimulated salivary flow rates than individuals not taking these drugs.
2 
Many studies have 
shown that the incidence of xerostomia may be directly proportionate to the amount of these 
drugs used by the patient.
20, 21 
 
The level of radiation that is required to destroy malignant cells ranges from 40-70 Gy, yet 
salivary gland tissue may be permanently damaged when exposed to radiation dosages which 
are greater than 30 Gy.
22 
Addington-Hall and McCarthy (1995) found that xerostomia was 
present in 30% of patients dying from cancer.
23 
Davies (2000) reported the prevalence of 
xerostomia as more than 30% in a mixed group of cancer patients and 77% in cancer patients 
admitted to a hospice.
24 
In a subsequent study they reported that in patients receiving 
chemotherapy for advanced cancer, the degree of xerostomia was proportionate to the 
number of chemotherapeutic agents used.
20     
 
1.2.2.3 Xerostomia and systemic illnesses 
There are several systemic disorders which are also associated with salivary gland 
hypofunction. These disorders include Sjögrenʹs syndrome, diabetes mellitus, sarcoidosis, 
human immunodeficiency virus, primary biliary cirrhosis, systemic lupus erythematosus, 
rheumatoid arthritis, depression, and cystic fibrosis. 
25 
Up to 42% of patients with rheumatoid 
arthritis suffer with xerostomia
26 
and patients with type I diabetes also have symptoms of dry 
mouth.
27 
Furthermore up to 43% of diabetic patients complained of dry mouth.
28 
 
19 
 
Sjögrenʹs syndrome is a chronic, inflammatory autoimmune disorder that is characterised by 
a lymphocytic infiltration of the salivary and lacrimal glands most commonly. This results in 
xerostomia and xerophthalmia. There are two forms of the disease, primary Sjögrenʹs 
syndrome and secondary Sjögren’s syndrome. In primary Sjögrenʹs syndrome the xerostomia 
and keratoconjunctivitis sicca occur as an isolated clinical entity whereas in secondary 
Sjögrenʹs syndrome, the xerostomia and keratoconjunctivitis sicca occur together with 
another autoimmune disease. The estimated prevalence of Sjögrenʹs syndrome in the 
population is 0.6%, with the highest prevalence in the fourth or fifth decade of life. 
25 
Sjögrenʹs syndrome predominantly occurs in women over the fourth decade.29  
1.2.3 Treatment of Xerostomia 
Due to the diminished saliva output, patients who suffer from xerostomia are at higher risk 
for dental caries and other oral infections. Thus they should be advised of a good oral hygiene 
regimen and the importance of regular dental visits. These patients should be advised to take 
frequent sips of water and to avoid caffeine and alcohol in order to prevent dehydration.  
A humidifier may also be used at night, when the xerostomia tends to worsen. Treatments for 
xerostomia may be divided into saliva substitutes and saliva stimulants. 
1.2.3.1 Salivary substitutes  
The most widely used saliva substitute is water, but milk also provides properties suitable for 
a salivary substitute. Milk provides excellent lubrication, and contains calcium and phosphate 
which aids in the buffering of acids as well as the remineralisation of teeth.
30 
Saliva substitute 
most commonly refers to artificial saliva. Artificial saliva may contain 
carboxymethylcellulose (CMC), glycerate polymer gel base, natural mucins or a 
mucopolysaccharide and may be presented as a rinse, gel or spray.  
20 
 
Artificial salivas may provide excellent relief of dry mouth but artificial saliva is not tolerated 
by patients and does not last
19 
and therefore, patients prefer saliva stimulants to saliva 
substitutes.
31 
 
1.2.3.2 Saliva stimulants 
Various saliva stimulants are presently available for the treatment of xerostomia. These 
include sugar free chewing gums, organic acids and parasympathatomimetics. Organic acids 
such as malic acid, ascorbic acid and citric acid will increase salivation but these acids also 
result in demineralisation of teeth. Therefore long-term use is not recommended for the 
treatment of xerostomia. Parasympathatomimetics are used in severe cases of xerostomia in 
order to increase saliva production. Pilocarpine is a nonspecific, muscarinic agonist which 
results in the parasympathetic stimulation of the exocrine glands in order to increase serous 
secretions.  
Pilocarpine is most commonly used in patients with Sjögrenʹs syndrome as well as patients 
that have received radiation therapy, in order to increase saliva flow. Nyárády et al (2006) 
conducted a prospective randomised study in order to assess the effectiveness of orally 
administered pilocarpine (Salagen
®
) during and after radiotherapy to the head and neck.
32 
This study found that patients who received 5mg of pilocarpine orally three times a day, from 
the beginning of radiotherapy as well as patients who only commenced this treatment 6 
weeks after start of radiotherapy, showed a significant increase in saliva production and 
decrease in symptoms related to xerostomia.  Similarly Zimmerman et al (1997) also found 
that pilocarpine administered during radiation therapy increased saliva production and 
decreased the symptoms of xerostomia.
33 
 
However Gornitsky et al (2004) found no significant increase in saliva production in patients 
treated with pilocarpine during radiation therapy as compared to a control group.
34 
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Furthermore, although pilocarpine may increase saliva flow, it is also associated with many 
parasympathetic side-effects such as gastro-intestinal disturbances, excessive sweating, 
increased pancreatic secretion, rhinitis, urinary disturbances, vasodilation and headaches. 
These side-effects have been shown to decrease patient compliance.
35 
Due to its 
parasympathetic effects, pilocarpine is contraindicated in patients with uncontrolled asthma, 
gastric ulcers, narrow-angle glaucoma, hypertension and patients on β-blockers. 
Cevimeline (Evoxac
®
) is another drug that is used to treat xerostomia in patients with 
Sjögrenʹs syndrome. Cevimeline, unlike pilocarpine, has specific affinity for receptor types 
that are not present in respiratory or cardiac tissue. Amifostine (intravenous), which is a thiol 
drug, is also used for the treatment of moderate to severe xerostomia in patients undergoing 
postoperative radiation treatment for head and neck cancer. Although Amifostine has the 
potential to reduce xerostomia during and post radiation treatment, a significant proportion of 
patients continue to experience xerostomia.
36
Although these parasympathatomimetic drugs 
may stimulate saliva flow and decrease the symptoms of xerostomia, their effects are not long 
lasting.  
1.2.3.3 Acupuncture 
Acupuncture involves the insertion of tiny needles at specific points, with the intent to 
prevent or cure diseases and symptoms.
37 
Braga et al  (2011) have shown that patients who 
received acupuncture treatments before and during the entire period of radiation therapy for 
head and neck cancer showed significant increase in saliva flow rates and decrease in 
xerostomia- related symptoms compared with patients in the control group, who did not 
receive acupuncture treatment.
38 
Furthermore, the effects of acupuncture on the secretion of 
saliva can be maintained for up to 6 months and with additional therapy, this improvement on 
saliva secretion may be maintained for up to 3 years.
39, 40
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1.2.4 Mouthrinses, Gels and Chewing gums  
Salivary glands can be stimulated by mechanical and gustatory stimuli, to increase the 
secretory capacity, for which gums and sucking tablets have been developed. They may 
contain antimicrobial compounds or enzymes and mouth wetting agents. Citric acid and 
vitamin C are also added into sucking tablets, which stimulates saliva flow.
4 
Decreased 
mastication results in an increased atrophy of the salivary glands.
41 
Therefore the salivary 
glands must be stimulated by masticatory or gustatory stimuli in order to prevent atrophy and 
to maintain saliva flow. 
 Sugar free chewing gum provides both masticatory and gustatory stimuli. Risheim and 
Arneberg (1993) found, in a study conducted on rheumatic patients, that sugar free chewing 
gum increases saliva flow by stimulating taste receptors.
42 
Abelson et al (1989) found that 
85% of saliva flow is related to gustatory stimulation and 15% is related to masticatory 
stimulation.
43 
Therefore flavoured chewing gums stimulate saliva flow to a greater degree 
than unflavoured chewing gums.
44 
Davies (2000) conducted a prospective randomised study 
on patients with advanced cancer. It was concluded that although both artificial saliva and 
chewing gum relieved xerostomia in these patients, more patients preferred chewing gum to 
artificial saliva.
24 
 
Xylitol is a natural sugar alcohol that is frequently added to chewing gums. S. mutans are 
unable to utilise xylitol resulting in less acid production and thus a decrease in plaque 
acidogenicity.
45 
Furthermore xylitol also affects the adhesiveness of S. mutans to tooth 
surfaces.
46 
It has been found that 6g/day of xylitol is required to affect the oral ecology.
47 
Similarly, Autio (2002) and Caglar et al (2007) have shown the levels of S. mutans to 
decrease in response to xylitol-containing chewing gum.
48, 49 
However, Twetman and 
Stecksén-Blicks (2003) found that although chewing xylitol containing gum decreased the 
23 
 
lactic acid concentration in supragingival plaque by 22%, in caries active children, as 
compared to chewing a control gum, the levels of S. mutans remained unaffected by both 
chewing gums.
 
This could be due to the high counts of S. mutans due to the carious lesions.
50 
 
1.3 Biotène® products  
Biotène
®
 products including chewing gum, toothpaste, gel, spray and mouthrinse are 
available in South Africa through GlaxoSmithKline. These products contain three primary 
enzymes, glucose oxidase, lactoperoxidase, and lysozyme which can replenish the salivary 
antibacterial properties. They also contain fluoride, calcium and xylitol. These products are 
claimed to fight cavities, periodontal disease and oral infections caused by dry mouth, 
according to the manufacturers packaging.  
The anti-microbial protein, lactoperoxidase, present in the Biotène
® 
has been well researched. 
Lactoperoxidase system generated hypothiocyanite ions (OSCN
-
) and hypothiocyanous acid 
(HOSCN) are inhibitory against a number of oral bacteria including mutans Streptococci.
51 
In 
vitro studies with Biotène
®
 dry mouth oral rinse have shown an antibacterial effect against S. 
mutans and Lactobacilli but not against C. albicans.
4 
A study conducted in elderly, 
institutionalised individuals with xerostomia with Biotène
®
 mouthwash, Biotène
®
 
Oralbalance gel and Biotène
®
 toothpaste also showed no effect on C. albicans counts as well 
as on dry mouth sensation.
52 
However, some studies have shown that Biotène
®
 has no effect 
on oral bacteria. Lenander-Lumikari et al (1993) as well as Kirstilä et al (1994) found that 
Biotène
®
 toothpaste did not induce antibacterial effects against total streptococci, S. mutans, 
Lactobacilli or the total anaerobic flora.
51, 53  
 
In addition, Kirstilä et al (1994) also found that plaque pH, acidogenicity and lactic acid 
production were unaffected by a 2 week daily use of Biotène
®
.
53 
In a subsequent study 
Kirstilä et al  (1996) showed that a 4 week Biotène
® 
toothpaste and Biotène
®
 mouthwash 
24 
 
regimen on 20 patients who suffered from chronic dry mouth symptoms resulted in a 
significant increase in the concentration of salivary hypothiocyanite and relieved dry mouth 
symptoms in xerostomic patients but once again there were no significant changes in the 
salivary microflora.
54 
Even in young individuals with a high caries activity, use of Biotène
®
 
mouthrinse has shown no effect on the S. mutans counts.
55
  
Although the above mentioned studies have shown that Biotène® has no effect on S. mutans 
counts, other studies have found Biotène® products to have many beneficial effects in the 
treatment of xerostomia.
56, 57, 58, 59, 60 
Nagy et al (2007) conducted a randomised, double-blind, 
placebo-controlled clinical study on Biotène
®
 products among 37 patients who had developed 
pronounced oral mucositis and xerostomia following radiation therapy. The results showed 
that there was a significant reduction in the counts of disease associated commensal oral 
aerobic and anaerobic bacteria. Furthermore there was a reduction in the counts of 
opportunistic candida species that are associated with radiation therapy. Most patients in the 
Biotène
®
 group showed a 50-100% improvement in whole resting saliva.
56 
Similarly, in the 
oral cavities of children, a significant reduction in S. mutans and Lactobacilli counts were 
found when they used Biotène
® 
toothpaste. Furthermore the test group showed a significant 
increase in the levels of thiocyanate ions (OSCN
-
) during the experimental as well as the 
washout periods, compared to the control group.
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 The hypothiocyanite ion is an important antimicrobial agent which is generated by the 
peroxidase system. OSCN
-
 has been shown to inhibit acid production by dental plaque
 61
, 
glucose uptake by cariogenic bacteria 
62  
and also inhibit the initial phases of dental caries.
63 
In a double-blind crossover study of the Biotène
®
 Oralbalance gel dry-mouth system and the 
BioXtra dry-mouth system in patients with post-radiotherapy xerostomia it was found that 
both systems were effective in alleviating symptoms of xerostomia. Both systems contain the 
hypothiocyanite ion. 
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 The BioXtra system was superior in the alleviation of certain symptoms when compared to 
the Biotène
®
 Oralbalance system. Furthermore, patients preferred the BioXtra system. 
Possible reasons for this could be because the viscosity of the BioXtra gel was 23 Pa.s which 
resulted in a longer retention time as compared to the Biotène
®
 Oralbalance gel which has a 
dynamic viscosity of 16.8 Pa.s.
57 
The BioXtra gel is formulated with minimal sweetening 
which may be better tolerated by patients and BioXtra also contains more peptides and 
immunoglobulins than Biotène
®
 Oralbalance. 
1.3.1 Biotène® chewing gums  
The Biotène
®
 range also includes Biotène
®
 chewing gum which can be used during the 
course of the day in order to provide relief of oral dryness, reduction of odour-causing 
bacteria as well as stimulate saliva flow according to the manufacturer. Biotène
®
 chewing 
gum contains Maltitol , Sorbitol , Gum Base , BHT , Xylitol , Artificial flavour , Titanium 
Dioxide , Lecithin , Resinous Glaze , Acesulfame K , Potassium Thiocyanate , 
Lactoperoxidase , Glucose Oxidase , Bees Wax and Carnauba Wax according to the 
manufacturers packaging. 
Biotène
®
 chewing gum in combination with other Biotène
®
 products has been used to 
alleviate oral discomfort due to xerostomia. Improvement in oral discomfort and intraoral 
dryness following a two month treatment with the Biotène
®
 system, composed of toothpaste, 
mouthwash and chewing gum, as well as Oralbalance gel have been reported in xerostomic 
patients receiving radiation therapy for head and neck cancer.
64 
However, the authors did not 
evaluate the effect on the oral microflora.  
Hyposalivation may occur in normal healthy individuals.
1, 2 
The effect of hyposalivation may 
not be drastic and the patient may experience subtle long term discomfort and changes. In this 
case simple measures can provide comfort in their daily life and prevent long term changes. 
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Ultimately, the only Biotène
®
 product that has not been subjected to extensive research is the 
chewing gum. Chewing gum might be more beneficial regarding saliva flow rate, acid 
clearance, accumulation of plaque and reduction of cariogenic bacteria as chewing gum 
stimulates saliva flow by offering mechanical stimulation of the salivary glands. In addition it 
is also convenient to chew gums during the course of the day without requiring water or a 
sink facility rather than using a mouthrinse or a gel. 
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1.4   AIM 
This study investigated the effect of Biotène
®
 chewing gum on the saliva flow rate, buffering 
capacity of saliva, plaque index and salivary levels of Streptococcus mutans and 
Lactobacillus in healthy subjects with hyposalivation. 
1.5   OBJECTIVES 
 To establish prevalence of hyposalivators in young adults 
 To study the effect of Biotène® chewing gum on the saliva production by 
hyposalivators 
 To examine the effect of Biotène® chewing gum on the buffering capacity and 
plaque index   
 To investigate the effect of Biotène® chewing gum on the salivary counts of 
Streptococcus mutans and Lactobacilli. 
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2   MATERIALS AND METHODS 
2.1 Study population 
Students enrolled for the Bachelor of Dental Sciences at The University of The 
Witwatersrand were approached. Ethical clearance from The Human Research Ethics 
Committee was obtained. (Appendix A) The study was explained to all students and those 
that agreed to take part signed the consent form (Appendix B). One hundred and nine dental 
students aged between 18 and 23 years were screened for their resting saliva secretion. 
Resting saliva secretion was obtained by asking students to sit quietly, without talking, and to 
collect saliva into a sterile sputum jar for 5 minutes. The jars were then taken to the lab and 
the saliva volume in each jar was measured using a graduated pipette and recorded. Students 
with a resting saliva flow rate of less than 0.3ml/min were considered having hyposalivation 
and included in the study. Hyposalivation in young, healthy individuals is rare as seen from 
the small sample size obtained thus a resting saliva flow rate below 0.3 ml/min, instead of 
below 0.1 ml/min, was used as a selection criteria as this enabled a larger sample size. The 
design of the study is included in appendix C (page 61). 
 
2.2 Baseline analysis 
At baseline tests, resting and stimulated saliva samples were collected which were also used 
to measure buffering capacity of saliva. Stimulated saliva was also used to measure bacterial 
counts such as S. mutans and Lactobacilli. In addition, an oral examination was performed to 
determine decayed, missing, filled teeth index (DMFT) and plaque index (PI). 
2.2.1 Collection of saliva 
Each student was given a number in order to maintain confidentiality. A baseline resting 
saliva flow rate and stimulated saliva flow rate was taken for each subject. Resting saliva 
flow rate was obtained by allowing subjects to sit quietly without talking and expectorate 
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saliva into a sterile sputum jar for 5 minutes. The volume of saliva was measured using a 
graduated pipette and recorded. The volume of saliva was then divided by 5 in order to obtain 
saliva flow rate/min and was recorded as the resting saliva flow rate before the use of the test 
products which were either xylitol chewing gum or Biotène
®
 chewing gum or the use of the 
saliva stimulant which was the inert rubber tubing.  
The stimulated saliva flow rate was obtained by asking subjects to chew a sterile piece of 
rubber tubing while continuously collecting saliva into a sterile sputum jar for 5 minutes. The 
volume of saliva was then divided by 5 in order to obtain saliva flow rate/min and was noted 
as the stimulated saliva flow rate before the use of the test products or the saliva stimulant. 
One ml of stimulated saliva was also taken to conduct the buffering capacity test (section 
2.2.2). The stimulated saliva was plated onto culture media for S. mutans and Lactobacilli 
counts (section 2.2.4).  
2.2.2 Buffering capacity of saliva 
One ml of each of the resting and stimulated saliva sample was transferred into sterile tubes 
Three ml of 0.005mol/L hydrochloric acid was then added into both the tubes. The two 
sample tubes were then closed, shaken and left open in order to allow carbon dioxide to 
escape. After 10 minutes the pH of the resting and stimulated saliva samples were measured 
using a pH meter.
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2.2.3 Oral examination and determination of “Decayed, missing, filled teeth” index 
 A Decayed, Missing, Filled, Teeth index (DMFT) was completed on each subject. A DMFT 
score was calculated for each subject in order to ensure that the subjects were similar 
regarding teeth affected by dental caries. This allowed a form of standardisation as the oral 
physiology of each individual is different.  
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The DMFT index was calculated in the following way: 
1. The number of teeth with existing dental decay was counted. 
2. The number of missing teeth was counted. (excluding third molars) 
3. The number of teeth with fillings was counted. This included teeth that had 
composite fillings, amalgam fillings, crowns or veneers. 
4. The total number of decayed, missing and filled teeth was then divided by the total 
number of teeth, in order to obtain a DMFT ratio for each subject. 
5. The ratio was then multiplied by 100 in order to determine the percentage of teeth 
that were affected by dental caries.  
An O’Leary plaque index was then completed on each subject in order to record plaque on 
tooth surfaces.
66 
Disclosing solution was first applied to all supragingival tooth surfaces using 
a large cotton pellet. Each subject was then asked to rinse his/her mouth in order to remove 
excess disclosing solution. Each tooth surface, except for the occlusal surface was examined 
for the presence of stained deposits at the dentogingival junction. If there was a stained 
deposit present on a tooth surface, it was recorded on the appropriate box in the plaque index 
form. The plaque index was then calculated by dividing the number of tooth surfaces with 
stained deposits by the total number of tooth surfaces scored. This number was then 
multiplied by 100 in order to obtain a percentage. 
2.2.4 S. mutans and Lactobacillus counts 
Two Mutans Bacitracin Agar (MBA) plates were used for each subject to obtain S. mutans 
counts. Tenfold dilution (1:10) was prepared from the stimulated saliva by adding 0.1 ml into 
0.9 ml phosphate buffered saline (PBS)  which was further diluted by adding 0.1 ml of 1:10 
dilution into 0.9 ml (1:100).  
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One hundred microlitres of each dilution was transferred on each of the MBA plates and 
evenly spread onto the surface using a sterile glass rod. Agar plates were incubated at 37
ᵒ
C 
for 48 hours under CO2.  
Two Rogosa Agar (RA) plates were used for each subject to obtain Lactobacillus counts. One 
hundred microlitres of stimulated saliva was transferred on to the RA plate surface 
(concentration) and spread with a sterile glass rod.  In addition 0.1 ml was transferred into a 
0.9 ml PBS solution (1:10 dilution) from which 0.1 ml was spread on a second RA plate. 
Agar plates were incubated at 37
ᵒ
C for 48 hours under CO2. After incubation, the number of 
S. mutans colonies on the MBA plates (dark blue, rough colonies) and the number of 
Lactobacilli colonies on the RA plates (creamy white colonies) were counted. The number of 
S. mutans and Lactobacilli present in the saliva were calculated by multiplying the number of 
colonies on the plates by the dilution factor of the plate and 10 because only 0.1 ml was 
tested. The counts were expressed per ml of saliva.  
2.3 Saliva stimulant or test products 
Biotène
®
 chewing gum, xylitol containing chewing gum (Stimorol
®
)
 
and an inert rubber 
tubing was used in this study. Biotène
®
 chewing gum also contains xylitol, therefore xylitol 
gums were included to eliminate the effect of xylitol from the Biotène
®
 chewing gum. 
Rubber tubing was used as a control to eliminate the chewing effect from each of the 
products. Following the baseline saliva analysis (section 2.2) the subjects were firstly given 
xylitol chewing gum and instructed to chew one piece of chewing gum for 10 min after meals 
or approximately every 2 hours. A total of 5 pieces of gum were chewed each day for 2 
weeks and the endpoint saliva analysis was then repeated (same as baseline analysis 
described in section 2.2) at the end of the 2-week period. After a wash off period (rest) of two 
weeks, the study was repeated with a repeat baseline saliva analysis. Instead of xylitol 
chewing gum, the subjects were asked to chew sterile pieces of inert rubber tubing. 
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 The chewing instructions were the same as for the xylitol chewing gum. The end point saliva 
analysis was done after 2 weeks, in the same way as described in section 2.2. After a wash off 
period (rest) of two weeks, the study was repeated with a repeat baseline saliva analysis. 
Instead of the sterile pieces of inert rubber tubing, the subjects were now asked to chew 
Biotène
®
 chewing gum. The chewing instructions were the same as for the xylitol chewing 
gum. The end point saliva analysis was done after 2 weeks.  
2.4 End point saliva analysis 
Following 2 weeks of xylitol chewing gum, rubber tubing, or Biotène
®
 chewing gum usage, 
an end point saliva analysis was conducted, same as described in the section 2.2 baseline 
analyses. Subjects were asked to bring back empty packaging of xylitol chewing gum, rubber 
tubing or Biotène
®
 chewing gum to ensure that all products were finished and to ensure the 
subject compliance.  
2.5 Ethical considerations 
The study protocol was approved by the Human Research Ethics Committee of the 
University of the Witwatersrand. Informed verbal consent was sought from participants. The 
following information was given to ensure that participants have information needed to make 
an informed choice; a complete description of the aims of the study, potential risks and 
benefits. 
2.6 Statistical analysis 
The STATA program was used to analyse the data. A two-tailed Wilcoxon signed-rank test 
was performed to establish if there was a difference between before and after values within a 
specific treatment option such as use of Xylitol chewing gum, Biotène
®
 chewing gum and 
inert rubber tubing. The chosen significance levels of the tests i.e the p-value was 0.05. 
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A two-tailed Kruskal-Wallis equality-of-populations test was performed to establish if there 
was a difference between the three treatment modalities. 
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3   RESULTS 
3.1 Hyposalivation 
One hundred and nine healthy subjects, 41(37.6%) male and 68(62.4%) females, were 
screened for hyposalivation. Only 18 subjects were found to have less than or equal to 0.3 
ml/min resting saliva and therefore they were considered hyposalivating subjects and 
included in the study. Of these 18 students only 13 agreed to participate in this study. In this 
small group of students that were screened, the prevalence of hyposalivation was 16.5%. 
(TABLE 1) 
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TABLE 1: Saliva production by subjects screened for hyposalivation 
SUBJECT 
NUMBER 
GENDER SALIVA 
FLOW 
(ml/min) 
 SUBJECT 
NUMBER 
GENDER SALIVA FLOW 
(ml/min) 
1 F 0.6 63 M 0.4 
2 F 0.4 64 F 0.3 
3 M 0.65 65 M 1.0 
4 F 0.65 66 M 0.5 
5 F 0.3 67 F 1.6 
6 F 0.65 68 F 0.4 
7 F 0.6 69 M 0.4 
8 F 0.47 70 M 0.5 
9 F 0.25 71 M 0.3 
10 F 0.9 72 F 0.4 
11 F 0.3 73 F 0.7 
12 M 0.9 74 F 0.2 
13 M 0.4 75 F 0.24 
14 F 0.4 76 F 0.24 
15 F 0.57 77 M 0.5 
16 M 0.6 78 M 0.6 
17 M 0.9 79 F 0.4 
18 F 1.4 80 M 0.5 
19 M 0.9 81 M 0.5 
20 F 1.0 82 M 0.5 
21 M 1.2 83 F 0.46 
22 M 1.5 84 F 0.5 
23 F 0.65 85 F 0.3 
24 M 1.5 86 F 0.46 
25 F 1.6 87 F 0.6 
26 F 0.35 88 F 0.6 
27 M 0.3 89 M 0.46 
28 F 0.8 90 F 0.5 
29 F 0.45 91 M 0.5 
30 F 0.45 92 M 0.6 
31 M 0.35 93 M 0.6 
32 M 0.7 94 F 0.24 
33 M 1.2 95 M 0.6 
34 M 1.0 96 F 0.5 
35 M 0.35 97 M 0.5 
36 F 0.45 98 F 0.4 
37 F 0.03 99 F 0.16 
38 F 0.65 100 F 0.6 
39 F 1.4 101 F 0.26 
40 M 0.53 102 F 0.4 
41 F 0.54 103 F 0.44 
42 F 1.5 104 M 0.46 
43 M 0.5 105 M 1.0 
44 M 0.1 106 F 0.4 
45 F 1.2 107 F 0.5 
46 F 2.8 108 F 0.5 
47 F 0.1 109 F 0.48 
48 M 1.5  Hyposalivating 
females=22% 
Hyposalivating     
males=7.3% 
hyposalivating 
subjects=16.5% 
 
49 M 1.1 
50 F 0.34 
51 F 0.1 
52 F 1.0 
53 F 1.14 
54 F 0.32  
 
 
55 F 1.1 
56 F 0.9 
57 F 0.8 
58 F 0.8 
59 M 0.4 
60 F 0.46 
61 M 0.5 
62 F 1.1 
F= Females Students with saliva flow less than or equals to 0.3 ml/min. 
M=Male 
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 3.2 Saliva flow 
Table 2 and figures 1 and 2 shows the resting and stimulated saliva flow rates of the 
hyposalivating subjects. Flow rate is expressed as millilitres of saliva per minute. The resting 
saliva sample was obtained while the subjects sat quietly while spitting into a sputum jar. The 
stimulated saliva sample was obtained while the subjects chewed a piece of inert rubber 
tubing while spitting into a sputum jar. Values were recorded before each treatment modality 
was started and also after 2 weeks use of each treatment modality and the control (rubber 
tubing, xylitol chewing gum or Biotène
®
 chewing gum).  
The mean resting saliva flow rates increased slightly after use of all three of the treatment 
modalities, with the greatest increase recorded after treatment with the xylitol chewing gum 
(Table 2, Figure 1). However none of the increases in the resting saliva flow rates among the 
three treatment modalities were considered statistically significant as none of the p-values 
were <0.05. It was seen that the mean stimulated saliva flow rate decreased after treatment 
with the rubber tubing. But this was not statistically significant.   
The mean stimulated saliva flow rates increased following the use of both xylitol chewing 
gum and Biotène
®
 chewing gum (Table 2, Figure 2). However, only the increase in the 
stimulated saliva flow rate after the xylitol chewing gum was considered statistically 
significant (p=0.05). The mean stimulated saliva flow rate decreased after treatment with the 
rubber tubing. 
 
37 
 
TABLE 2: Resting saliva flow and stimulated saliva flow of hyposalivating subjects before and after the use of rubber tubing (control), 
xylitol chewing gum and Biotène
®
 chewing gum. 
Subjects Resting saliva flow (ml/min) Stimulated saliva flow (ml/min)  
 Rubber tubing xylitol chewing gum Biotène® chewing 
gum 
Rubber tubing xylitol chewing gum Biotène® chewing gum 
 
 Before After Before After Before After Before After Before After Before After 
1 1.0 0.9 0.55 0.3 0.8 1.0 1.94 1.14 1.32 0.8 1.66 2.0 
2 0.6 0.9 0.2 1.3 0.7 1.12 1.6 1.54 1.82 2.14 1.28 1.7 
3 0.4 0.34 0.55 0.3 0.3 0.4 0.84 0.62 0.77 0.9 0.74 0.7 
4 0.3 0.3 0.3 0.7 1.1 0.8 1.24 1.14 0.74 1.0 1.5 1.4 
5 0.5 0.9 0.4 0.3 0.46 0.4 1.04 0.94 0.64 0.54 0.68 0.74 
6 0.6 0.4 0.4 0.4 0.42 0.3 0.84 0.84 0.44 0.84 1.1 0.62 
7 0.64 0.64 0.4 0.5 0.7 0.62 0.82 0.74 0.64 0.84 0.34 0.88 
8 0.4 0.4 0.4 0.9 0.5 0.42 0.56 0.7 0.64 0.94 0.3 0.68 
9 0.8 1.1 0.5 0.8 0.82 1.4 0.9 1.4 0.8 1.2 1.22 1.74 
10 0.2 0.24 0.3 0.1 0.1 0.2 0.58 0.3 0.4 0.4 0.38 0.3 
11 0.76 0.72 0.5 1.3 0.6 0.8 0.82 0.9 0.84 1.4 0.64 1.38 
12 0.14 0.38 0.1 0.1 0.1 0.22 0.32 0.7 0.26 0.56 0.4 0.42 
13 0.7 0.74 0.4 0.54 0.7 0.5 1.0 0.9 0.84 0.7 0.86 0.68 
Mean 0.54 0.61 0.38 0.58 0.56 0.63 0.96 0.91 0.78 0.94 0.85 1.02 
SD 0.24 0.28 0.13 0.4 0.29 0.37 0.43 0.33 0.4 0.45 0.46 0.55 
P value 0.3067 0.1714 0.3449 0.4625 0.0589 0.1961 
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Figure 1: Effect of the rubber tubing, xylitol chewing gum and Biotène
®
 chewing 
gum on the resting saliva flow of subjects with hyposalivation. 
 
 
Figure 2: Effect of the rubber tubing, xylitol chewing gum and Biotène
®
 chewing 
gum on the stimulated saliva flow of subjects with hyposalivation. 
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3.3 Buffering capacity 
Table 3 shows the resting buffering capacity of the saliva and the stimulated buffering 
capacity of the saliva in the thirteen subjects. The resting buffering capacity was obtained 
from the resting saliva sample in each subject whereas the stimulated buffering capacity was 
obtained from the stimulated saliva sample in each subject. Both resting and stimulated 
buffering capacities were recorded for each subject before and after each treatment modality. 
The mean resting buffering capacity was shown to increase after treatment with rubber tubing 
but decrease after treatment with xylitol chewing gum and also Biotène
®
 chewing gum 
(Figure 3). However, none of these changes were statistically significant as the p-values were 
> 0.05.  
The mean stimulated buffering capacity of the saliva was again shown to increase after 
treatment with rubber tubing but decrease after treatment with xylitol chewing gum and 
Biotène
®
 chewing gum (Figure 4). None of these changes were said to be statistically 
significant as none of the p-values were < 0.05.  
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TABLE 3: Buffering capacity of resting and stimulated saliva in subjects with hyposalivation before and after the use of rubber tubing 
(control), xylitol chewing gum and Biotène
®
 chewing gum.  
Subjects Buffering capacity of resting saliva (pH) Buffering capacity of stimulated saliva (pH)  
 Rubber tubing xylitol chewing gum Biotène® chewing 
gum 
Rubber tubing xylitol chewing gum Biotène® chewing gum 
 
 Before After Before After Before After Before After Before After Before After 
1 4.08 3.67 3.26 3.94 3.62 4.91 5.81 4.94 4.82 4.75 5.59 6.15 
2 3.85 4.21 3.94 3.23 3.85 4.01 3.90 4.91 4.20 3.31 4.00 4.48 
3 4.16 4.14 3.60 3.36 4.52 3.55 3.60 4.70 3.10 3.35 4.85 4.65 
4 5.62 5.09 3.34 3.43 4.44 5.75 4.92 6.02 3.58 3.66 5.15 6.00 
5 2.96 2.71 2.94 2.86 5.35 4.03 3.15 3.09 3.48 3.11 5.83 4.91 
6 3.81 3.52 2.94 3.18 3.42 2.93 3.41 3.83 2.97 3.35 4.32 3.12 
7 4.26 3.92 3.63 3.31 5.28 4.91 5.24 4.33 3.63 4.45 5.81 5.80 
8 2.94 5.24 2.88 3.44 4.79 3.91 3.04 3.99 2.83 3.10 4.58 3.26 
9 3.64 5.24 5.45 4.92 5.58 4.82 3.59 5.27 4.88 5.24 5.75 4.76 
10 3.69 3.74 2.83 3.04 3.14 3.00 3.45 3.54 2.81 2.69 3.36 2.85 
11 4.77 4.66 4.65 4.47 4.86 3.99 4.55 4.33 4.87 4.03 4.57 4.20 
12 4.33 4.25 4.27 3.80 3.62 4.63 4.77 4.62 3.84 4.93 4.42 4.64 
13 4.64 3.93 3.75 4.19 3.75 4.52 5.05 3.67 4.53 3.37 3.96 4.31 
Mean 4.06 4.18 3.65 3.63 4.32 4.23 4.19 4.40 3.81 3.80 4.78 4.54 
SD 0.72 0.74 0.78 0.6 0.81 0.80 0.90 0.79 0.78 0.80 0.80 1.05 
P value 0.4631 0.8339 0.7532 0.3822 0.9721 0.2787 
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Figure 3:   Effect of the rubber tubing, xylitol chewing gum and Biotène
®
 chewing 
gum on the buffering capacity of resting saliva in subjects with 
hyposalivation. 
 
 
 
Figure 4:   Effect of the rubber tubing, xylitol chewing gum and Biotène
®
 chewing 
gum on the buffering capacity of stimulated saliva in subjects with 
hyposalivation. 
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 0 
3.4 DMFT and Plaque index 
Table 4 shows the plaque indices of the study subjects. A plaque index was recorded before 
and after use of each treatment modality. The plaque index was expressed as a percentage. 
The mean plaque index decreased after treatment with the rubber tubing and the xylitol 
chewing gum but remained unchanged after treatment with the Biotène
®
 chewing gum. 
However, only the plaque index decrease following xylitol chewing gum treatment was 
considered statistically significant with a p-value of 0.0019 (Table 4 and Figure 5). 
Table 5 shows the total number of teeth present in each of the subjects as well as their DMFT 
scores.  The DMFT scores were used to ensure that the subjects were standardised and that 
they did not have too many teeth that were affected by dental caries. The DMFT ratio 
describes how much of each subject’s dentition has been affected by dental caries. The 
DMFT percentage provides the percent of decayed, missing and filled teeth present in each 
subject.  The DMFT ratio ranged from 0 to 0.32. Therefore the DMFT ranged from zero teeth 
being affected by dental caries to 32% of teeth being affected by dental caries. There was a 
mean DMFT ratio of 0.08 with a mean DMFT percentage of 8.1%. Therefore there was a 
mean of 8.1% of teeth that were affected by dental caries.   
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TABLE 4: Plaque index in subjects before and after the use of rubber tubing (control), 
xylitol chewing gum and Biotène
®
 chewing gum. 
 
 
Figure 5:   Effect of the rubber tubing, xylitol chewing gum and Biotène
®
 chewing 
gum on the plaque index of subjects with hyposalivation. 
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Subjects Plaque Index (%) 
 Rubber tubing xylitol chewing 
gum 
Biotène® chewing 
gum 
 Before After Before After Before After    
1 66.9 75.8 70.5 46.4 53.5 53.5 
2 25 46 74.2 49.2 41.4 31.25 
3 66.6 30.8 88.3 33.3 30 43.3 
4 57.1 66.9 78.5 56.2 26.7 31.2 
5 53.5 58 84.8 66.9 44.6 18.75 
6 19.7 8.3 67.7 50 8.3 10.4 
7 52.6 44.6 83.9 84.8 45.5 53.5 
8 55 25 73.9 30 23.9 21.8 
9 23 44.2 73 14 38.4 37.5 
10 26.6 29.1 66.6 29 34 46.6 
11 33 30.3 100 21.4 10.7 12.5 
12 28.5 22.3 59.8 44.6 31 32.1 
13 62.5 16.9 92.8 66 17.8 15.1 
Mean 43.8 38.3 78 45.5 31.2 31.3 
SD 18.0 19.9 11.4 20.0 13.7 15.0 
P value 0.5067 0.0019 0.6245 
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TABLE 5: DMFT results of hyposalivating subjects. (n=13) 
SUBJECT NUMBER TOTAL NUMBER 
OF TEETH 
PRESENT 
DMFT RATIO DMFT 
PERCENTAGE 
(%) 
1 28 0 0 
2 28 0.32 32 
3 28 0 0 
4 28 0.04 4 
5 28 0.04 4 
6 24 0.04 4 
7 28 0 0 
8 28 0.21 21 
9 26 0.12 12 
10 28 0.07 7 
11 24 0.17 17 
12 28 0 0 
13 28 0.04 4 
MEAN 27.2 
 
0.08 
 
8.1 
 
SD 1.5 
 
0.1 
 
9.8 
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3.5 S. mutans and Lactobacilli counts 
Table 6 and Figure 6 show the quantity of S. mutans and Lactobacilli present in the saliva of 
the thirteen subjects. These values were expressed as colony forming units per millilitre of 
saliva and were obtained before and after each treatment modality for each subject. The mean 
S. mutans counts decreased following treatment with rubber tubing and xylitol chewing gum. 
The decrease in S. mutans count was only statistically significant following rubber tubing 
treatment (p=0.0015). The mean S. mutans count following treatment with Biotène
®
 chewing 
gum was shown to increase but this was not statistically significant.  
The mean Lactobacilli count increased following treatment with rubber tubing but this was 
not statistically significant. The mean Lactobacilli count was shown to decrease following 
treatments of xylitol chewing gum and Biotène
®
 chewing gum. These decreases in 
Lactobacilli counts were considered statistically significant (p<0.05). (Table 6, Figure 7) 
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TABLE 6: S. mutans and Lactobacilli counts in hyposalivating subjects before and after the use of rubber tubing (control), xylitol 
chewing gum and Biotène
®
 chewing gum. 
TNTC-too numerous to count or number          OVERGROWTH- plate had overgrowth of gram –ve organisms obscuring S. mutans 
 
 
Subjects S. mutans count (CFU/ml) Lactobacilli count (CFU/ml)  
 Rubber tubing xylitol chewing gum Biotène® chewing 
gum 
Rubber tubing xylitol chewing gum Biotène® chewing gum 
 
 Before After Before After Before After Before After Before After Before After 
1 1.5×105 6.2×104 5.1×104 5.0×105 4.2×104 5.0×104 0 0 1.3×102 0 0 1.5×102 
2 Overgrowth 9.5×103 1.1×105 5.6×105 1.5×105 5.8×105 0 0 0 0 0 0 
3 1.5×105 7.1×105 3.5×105 1.9×106 2.2×105 1.9×105 5.0×101 0 1.6×102 4.5×102 3.0×101 0 
4 2.3×105 3.8×104 3.6×105 9.2×104 9.0×103 1.4×105 1.4×104 3.2×103 1.3×104 1.5×104 5.2×103 4.2×103 
5 6.5×104 1.6×104 3.1×106 1.5×105 2.3×104 2.3×103 0 1.0×101 0 0 4.0×101 1.0×101 
6 8.5×103 2.1×106 6.6×105 4.1×105 4.7×105 2.0×105 0 1.5×105 2.5×104 2.8×103 1.1×103 3.5×102 
7 1.5×105 1.2×105 2.5×105 2.4×105 4.2×105 4.2×105 0 1.0×101 1.6×102 0 1.0×101 2.7×102 
8 7.1×104 8.6×103 2.8×104 3.0×103 9.3×103 1.6×104 0 0 0 0 0 0 
9 7.4×104 8.6×104 2.3×104 4.5×104 2.4×104 2.3×105 1.8×102 1.4×103 1.6×103 9.3×102 7.0×101 9.5×102 
10 1.4×105 5.3×105 1.9×106 5.1×105 8.1×105 2.2×106 6.2×104 1.0×104 2.8×104 TNTC 9.8×104 TNTC 
11 1.5×106 5.7×105 1.1×106 2.6×105 4.3×105 2.6×104 9.5×103 7.7×103 5.3×103 8.2×102 1.3×104 9.6×103 
12 2.1×105 7.4×105 8.4×105 3.0×105 2.7×105 2.1×105 5.0×101 9.5×103 1.5×102 2.6×102 1.4×103 8.5×101 
13 2.4×106 4.8×105 1.7×105 3.3×105 4.8×105 2.1×105 1.8×103 3.6×103 4.3×103 1.9×103 1.4×104 2.2×103 
Mean 7.7×105 5.9×105 9.0×105 4.8×105 2.4×105 5.8×105 1.7×104 4.1×104 9.8×103 4.4×103 2.7×104 2.8×103 
SD 152500 117000 348000 300000 220500 198250 50 1425 160 445 70 265 
P value 0.0015 0.3824 1.0000 0.6981 0.0057 0.0058 
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Figure 6:   Effect of the rubber tubing, xylitol chewing gum and Biotène
®
 chewing 
gum on the S. mutans counts of subjects with hyposalivation. 
 
 
 
Figure 7:   Effect of the rubber tubing, xylitol chewing gum and Biotène
®
 chewing 
gum on the Lactobacilli counts of subjects with hyposalivation. 
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3.6 Summary results of test parameters after the use of test products. 
Table 7 shows a comparison of each treatment modality within each different parameter. The 
p-values for each parameter have been noted as well as the difference in the mean before and 
after values which are represented as a percentage.  
The changes in resting saliva flow were not statistically significant with all treatment 
modalities (p>0.05). The changes in stimulated saliva flow following use of rubber tubing 
and Biotène
®
 were not statistically significant (p>0.05) but was statistically significant 
(p=0.05) following the use of xylitol chewing gum. The changes in resting and stimulated 
buffering capacity following use of all three products were not statistically significant 
(p>0.05). The changes noted in the plaque index following the uses of rubber tubing and 
Biotène
®
 chewing gum were not statistically significant (p>0.05), however the change in 
plaque index following the use of xylitol chewing gum was statistically significant (p<0.01). 
The change in S. mutans count was statistically significant (p<0.05) following the use of 
rubber tubing but not significant (p>0.05) following use of xylitol chewing gum or Biotène
®
 
chewing gum. The change in Lactobacilli count was not statistically significant (p>0.05) 
following use of rubber tubing but was statistically significant (p<0.05) following use of 
xylitol chewing gum and Biotène
®
 chewing gum. 
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Table 7: Summary results of test parameters after the use of test products. 
Tests % Increase (+) or (-) decrease (p value) 
 Rubber tubing xylitol chewing gum Biotène® chewing 
gum 
 Before and After 
compared 
Before and 
After compared 
Before and 
After compared 
Resting saliva flow +13.0 (0.3) +52.6 (0.17) +12.5 (0.34) 
Stimulated saliva flow -5.2 (0.46) +20.5 (0.05) +20.0 (0.19) 
Buffering capacity of saliva at rest +3.0 (0.46) -0.5 (0.83) -2.1 (0.75) 
Buffering capacity of saliva after 
stimulation 
+5.0 (0.38) -0.3 (0.97) -5.0 (0.27) 
Plaque index -5.5 (0.5) -32.5 (<0.01) +0.1 (0.62) 
S. mutans counts -23.4 (<0.01) -46.7 (0.38) +141.7 (1.0) 
Lactobacilli counts +141.2 (0.7) -55.1 (<0.01) -89.6 (<0.01) 
 
Saliva flow and buffering capacity should increase. Plaque index and bacterial counts should 
decrease. 
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4   DISCUSSION 
4.1 Saliva production by subjects screened for hyposalivation 
109 subjects were screened for hyposalivation. We found that 16.5% of these subjects were 
hyposalivators with a resting saliva flow rate that was less than or equal to 0.3ml/min. Our 
results are thus in agreement with Yamamoto et al (2011) who found that hyposalivation does 
occur in healthy, young individuals.
1 
 
Our results also showed that 7.3% of males and 22% of females were hyposalivators (resting 
saliva flow rate less than or equal to 0.3ml/min). Thus our study showed that hyposalivation 
was much more prevalent amongst females than men, which is in agreement with other 
studies.
2, 16
 It is rare for hyposalivation to be present amongst young, healthy individuals. A 
possible explanation for the presence of hyposalivation amongst this group of subjects may 
be due to stress. 
4.2 Resting and stimulated saliva flow rates 
Saliva is important for the maintenance of good oral health as it provides immunological 
protection, aids in the production of the food bolus, provides lubrication and also provides an 
ion reservoir which contributes to the remineralisation of teeth. Furthermore a constant flow 
of saliva is required to eliminate bacteria, plaque and food debris. Saliva can be collected at 
rest or with stimulations. Resting saliva flow rate can be defined as the flow of saliva which 
occurs in the absence of any physiological or oral stimulation whereas the stimulated saliva 
flow rate is defined as the flow of saliva which occurs in the presence of oral or physiological 
stimulation. 
Our results showed that there were increases in resting saliva flow rates following the use of 
rubber tubing (13%), xylitol containing chewing gum (52.6%) and Biotène
®
 chewing gum 
(12.5%).  This suggests that if the salivary glands are constantly stimulated due to 
51 
 
masticatory stimulation, which was provided by all three test products, there will be an 
increase in saliva flow rate. The greatest increase in resting saliva flow rate was noted 
following the use of xylitol containing chewing gum (52.6%), which suggests that xylitol 
provides better gustatory stimulation compared to the inert control or enzyme containing 
Biotène
®
. Although all the test products increased the resting saliva flow, there was no 
statistical significance in any of the groups. 
Various saliva substitutes and stimulants have been developed in order to alleviate the 
debilitating effects of dry mouth. Chewing gums have proven to be a popular treatment 
alternative amongst hyposalivators and offer masticatory stimulation as well as gustatory 
stimulation.
24 
However if the hyposalivation has occurred due to damage to the salivary 
glands, this regime may not provide benefit. These products can provide benefit if the 
hyposalivation has occurred due to other reasons such as use of medication or due to 
dehydration. 
In our results there were increases in stimulated saliva flow rates following use of xylitol 
chewing gum (20.5%) as well as following the use of Biotène
® 
chewing gum (20%). The 
increase following use of xylitol chewing gum was statistically significant with a p-value of 
0.05. These results are not unexpected as chewing gums have been shown to offer gustatory 
stimulation of the salivary glands.
24 
However, a decrease of 5.2% was noted in the stimulated 
saliva flow rate following use of the rubber tubing which cannot be explained. 
The xylitol chewing gum was shown to be most effective in increasing both resting and 
stimulated saliva flow rates. A possible explanation for this may be that xylitol chewing gum 
offers a better taste than rubber tubing or Biotène
® 
chewing gum. Sugar free chewing gum 
increases saliva flow by stimulating taste receptors.
42 
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Furthermore, Dawes and Kubleniec (2004) found that a twofold increase in saliva flow rate 
occurs when the sweeteners and flavour is at a maximum and this increase is then maintained 
for as long as the gum continues to be chewed.
67 
Thus xylitol chewing gum produced the best 
result in increasing resting and stimulated saliva flow rates possibly due to a more acceptable 
gustatory stimulus.     
4.3 Buffering capacity of resting and stimulated saliva 
The buffering capacity of saliva is very important in the maintenance of a normal salivary pH 
of about 6.6 in resting saliva and 7.4 for stimulated saliva.
68 
The mechanism of buffering 
capacity is dependent on the concentration of bicarbonate ions present in the saliva. Due to 
repeated acid exposure in the oral cavity, there is an increase in hydrogen ions which results 
in a decrease in the pH of saliva. Demineralisation of enamel occurs after the pH of saliva 
drops below 5.5. Carbonic anhydrase is an enzyme which catalyses the reaction between the 
free hydrogen ions and the bicarbonate ions, which are present in the saliva, resulting in the 
production of carbon dioxide gas and water, which is in turn expelled from the oral cavity. 
Therefore if there are more bicarbonate ions present in the saliva, more free hydrogen ions 
will be bound and the pH of saliva will return to normal faster resulting in less damage to the 
enamel. The buffering capacity of saliva has been shown to have a positive correlation with 
salivary flow rate 
69
, thus any factor that decreases saliva flow rate will also decrease its 
buffering capacity.
70 
 
Our results showed a positive correlation between saliva flow rate and buffering capacity 
following the use of rubber tubing. They however failed to show a positive correlation 
between saliva flow rate and buffering capacity for xylitol chewing gum and Biotène
®
 
chewing gum which is contrary to previous findings.
71  
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Fenoll-Palomares et al (2004) found, in an observational prospective study on 159 volunteers, 
that there was a positive correlation between saliva flow rate and bicarbonate concentration.
71 
 
4.4 Plaque index and DMFT score 
A plaque index is calculated in order to measure the state of oral hygiene of an individual, as 
it is able to assess the level of plaque accumulation on tooth surfaces. The plaque index is 
often used by dental practitioners for dental education purposes and also to monitor oral 
hygiene progress of patients. The O’Leary plaque index is commonly used and was also used 
in our study.
66 
 
Our results showed a decrease in plaque index to have occurred after use of rubber tubing 
(5.5%) and xylitol chewing gum (32.5%). The decrease in plaque index following the use of 
xylitol chewing gum was statistically significant (p=0.0019). Xylitol chewing gum has been 
shown to significantly decrease the plaque index in children.
72, 73
 Increased saliva flow often 
eliminates bacteria, plaque and food debris. Thus from our results it can also be seen that 
there is a positive correlation between saliva flow and a decreased plaque index, as xylitol 
chewing gum was shown to be most effective in increasing saliva flow ( by 53%) as well as 
decreasing plaque index by 32.5%. 
Biotène
®
 chewing gum had no effect on the plaque index which shows that although this gum 
had antimicrobial enzymes, it did not reduce the amount of plaque. Biotène
® 
chewing gum 
also contains xylitol. One possible explanation for this could be that the levels of xylitol in 
the Biotène
®
 chewing gum may not be as high as that in the xylitol chewing gum.  
The DMFT ratios are an indication of how many teeth in the subjects mouths have been 
affected by dental caries. A higher DMFT score would indicate that more teeth in the 
subject’s mouth had been affected by dental caries. 
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 Plaque contains large amounts of cariogenic bacteria such as S. mutans. Thus it follows that 
if there is a high plaque index, there will be more cariogenic bacteria in contact with tooth 
surfaces for a longer period of time, which may result in cavity formation and thus a higher 
DMFT score. The DMFT ratio was taken in order to standardise the subjects. The mean 
DMFT ratio was very good at a value of 0.1 which indicates that the subjects had relatively 
few teeth that were affected by dental caries. 
4.5 Salivary S. mutans and Lactobacilli counts  
Streptococcus mutans is a gram-positive, facultatively anaerobic bacteria that is found in the 
oral cavity and that has been shown to contribute to dental caries. S. mutans is an early 
coloniser of the tooth surface which grows and metabolises carbohydrate, thus allowing other 
organisms to colonise the tooth surface and eventually form dental plaque.  In addition, S. 
mutans metabolises sucrose to form lactic acid which results in demineralisation of enamel. 
Many treatments, such as Biotène
®
, have been developed in order to decrease S. mutans, thus 
decreasing their deleterious effect on mineralised structures in the oral cavity.   
Our results showed that there was a decrease in the S. mutans count following the use of 
rubber tubing (23.4% based on mean) and xylitol chewing gum (46.7% based on mean). But 
only the decrease in S. mutans count following rubber tubing use was statistically significant 
(p=0.0015). These results suggest that chewing on anything that provides masticatory 
stimulation might be sufficient to decrease the S. mutans counts. The effect of xylitol on the 
S. mutans count is controversial. Autio (2002) showed that xylitol decreases salivary S. 
mutans counts.
48 
However, Twetman and Stecksén-Blicks (2003) found that xylitol did not 
decrease salivary S. mutans counts but this result may have been due to the low quantity of 
xylitol that was used per day.
50 
Twetman and Stecksén-Blicks
 
(2003) only administered 
5g/day of xylitol, but 6g/day of xylitol is required to affect the oral ecology.
47  
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Thus the quantity of xylitol in the chewing gum is also an important factor in reduction of S. 
mutans. There was possibly a larger quantity of xylitol in the xylitol gum than the Biotène
®
 
chewing gum. This could have been the reason why a reduction in the S. mutans count was 
recorded following the use of xylitol gum but not following the use of Biotène
®
 chewing 
gum. 
The exact amount of xylitol present in both xylitol chewing gum and Biotène
®
 chewing gum 
is, unfortunately, unknown as the manufacturers do not make this information available. Our 
results also showed increase in S. mutans count due to Biotène
®
 chewing gum by 141.7% 
(not statistically significant) which is contrary to what has been expected of this chewing 
gum. Biotène
®
 chewing gum contains glucose oxidase and lactoperoxidase which inhibit      
S. mutans. Thus the S. mutans count should have decreased. 
 Lactoperoxidase has been shown to inhibit a number of oral bacteria including S. mutans
51
, 
yet Biotène
®
 chewing gum in our study resulted in an increase in S. mutans count. In lab 
conditions Biotène
®
 was shown to be superior to Zendium toothpaste, which is another 
product that has been designed with the same purpose as Biotène® and that also contains 
lactoperoxidase , in inhibiting the growth of S. mutans and Lactobacilli
74
, yet in vivo studies 
showed that Biotène
®
 toothpaste, containing the peroxidase system components, did not show 
any antibacterial effects against total streptococci, S. mutans, Lactobacilli or the total 
anaerobic flora.
51, 53
 Kocak et al (2009) also found that Biotène
®
 mouth rinse which contained 
glucose oxidase, Lactoperoxidase, and Lysozyme had no effects on salivary S. mutans 
levels.
55
All these previous studies usually focused on Biotène
®
 toothpaste, gel,  mouth rinse, 
or a combination of toothpaste, mouth rinse, gel and chewing gum, with none of the studies 
exclusively utilising Biotène
®
 chewing gum. 
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Lactobacilli are gram positive, facultatively anaerobic bacteria that are found in the oral 
cavity and have been implicated in the progression of dental caries. Lactobacilli produce 
lactic acid from sugars. This lactic acid causes demineralisation of dental enamel. Treatments 
have also been developed to decrease Lactobacilli counts, thus preventing excessive lactic 
acid production and the subsequent demineralisation of dental enamel.    
In our study Lactobacilli counts were shown to increase following rubber tubing use 
(141.2%). There were decreases in Lactobacilli counts following use of xylitol chewing gum 
and Biotène
®
 chewing gum by 55.1% and 89.6% respectively. Both decreases were 
statistically significant with p-values <0.01. This suggests that xylitol which is present in both 
the products has antibacterial effects against Lactobacilli. In addition, Biotène
®
 has additional 
antibacterial effects against Lactobacilli because the reduction was greater by 34.5% 
compared to the xylitol gum. 
Caglar et al (2007) found that there was no significant decrease in salivary Lactobacilli 
counts following use of 6g/day of xylitol chewing gum for a period of 3 weeks.
49 
However 
our results show a decrease in Lactobacilli count of 55.1% following use of xylitol chewing 
gum which possibly contains a large quantity of xylitol. This decrease is in agreement with 
findings by Mäkinen et al (2008) who found that the levels of salivary Lactobacilli were 
significantly decreased following the use of xylitol containing chewing gums.
75
Although the 
2 weeks use of Biotène
®
 toothpaste which contained a lactoperoxidase system, showed no 
notable changes in the Lactobacilli counts
53
, our results showed a decrease in counts which is 
in agreement with Jyoti et al (2009) who found that salivary Lactobacilli counts were 
significantly reduced following use of lactoperoxidase containing Biotène
®
 toothpaste.
59 
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4.6 Summary results of test parameters after the use of test products. 
There were no statistically significant changes in resting saliva flow rate following rubber 
tubing, xylitol chewing gum or Biotène
®
 chewing gum. The small increases in resting saliva 
flow following the use of rubber tubing, xylitol and Biotène
®
 chewing gum could be simply 
attributed to a masticatory stimulus as the increases were very similar. Therefore the Biotène
®
 
chewing gum did not result in any greater benefit in terms of resting saliva flow as compared 
to any inert masticatory stimulus. 
 Stimulated saliva flow was not significantly affected by rubber tubing or by Biotène
®
 
chewing gum but was significantly affected by xylitol chewing gum (p=0.05). Again xylitol 
chewing gum has been shown to offer the greatest increase in stimulated saliva flow, when 
compared to rubber tubing or Biotène
®
 chewing gum. 
There was no effect on the buffering capacity by either chewing or the stimulants such as 
xylitol or enzymes which is surprising because stimulated saliva usually contains 7 times 
more bicarbonate compared to the resting saliva.
76
  
Xylitol significantly decreased the plaque index (by 32.5%) which can be explained by the 
increase in the saliva flow by 53%. A constant flow of saliva eliminates bacteria, plaque and 
food debris which reduces plaque development.  Rubber tubing resulted in a decrease in 
plaque index (5.5%) as rubber tubing offered masticatory stimuli thus increased saliva flow 
slightly (13%) which in turn decreased retention of plaque on tooth surfaces. Xylitol chewing 
gum also offered a masticatory stimulus but in addition contained xylitol, which has been 
shown to significantly decrease plaque index in children.
72, 73 
Thus xylitol chewing gum was 
shown to be the most effective in decreasing plaque index. However Biotène
® 
chewing gum 
has not been proven to affect plaque index.    
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Rubber tubing resulted in a 23.4% decrease in S. mutans count which was statistically 
significant (p=0.0015). This could have been due to some missing data due to overgrowth of 
gram negative organisms in this group. This occurs in cases where the individual was 
carrying gram negative bacilli (gut flora) in their saliva. This situation would have occurred if 
the individual had extremely poor oral hygiene or was immunocompromised. Even if xylitol 
chewing gum resulted in a 46.7% decrease in S. mutans count it was not significant because 
the results varied tremendously with a high standard deviation. In addition, a larger sample 
size is required to achieve a meaningful result.  
Biotène
®
 chewing gum should have resulted in the greatest decrease in S. mutans count as it 
provides a masticatory stimulus, xylitol as well as host proteins but instead it resulted in a 
great increase in S. mutans count. It is possible that the quantity of xylitol is not substantial 
enough to affect the S. mutans counts. Also it may be possible that one of the components in 
the Biotène
®
 chewing gum renderes the host proteins ineffective. Another possibility is a 
poor, cariogenic diet which may have been adopted by the subjects during the use of 
Biotène
®
 chewing gum.  
Rubber tubing which offered only masticatory stimulation increased Lactobacilli counts 
(141.2%) which were possibly due to dietary influences in the subjects during the rubber 
tubing phase of the study. The decrease in Lactobacilli count following the use of xylitol 
chewing gum may be attributed to xylitol which has been shown to decrease salivary 
Lactobacilli.
75
 Biotène
®
 was shown to be more effective than xylitol chewing gum in 
reducing Lactobacilli counts. This was possibly due to the presence of host proteins in the 
Biotène
®
 chewing gum. Thus the only parameter where Biotène
®
 chewing gum was shown to 
be effective in was in Lactobacilli count reduction.  
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5   CONCLUSION 
The prevalence of hyposalivation among the study population was 16.5%. Chewing gum 
containing natural host proteins, Biotène®, did not increase resting and stimulated saliva 
significantly in hyposalivating subjects. Biotène
®
 had no effect on the buffering capacity of 
resting and stimulated saliva. In addition, Biotène
®
 did not reduce the plaque index and 
salivary Streptococcus mutans counts. However, it reduced the salivary Lactobacilli counts 
significantly. Xylitol chewing gum which was used as a second control to eliminate the effect 
of xylitol from the Biotène
®
 showed significant increase in the stimulated saliva, reduced 
plaque index and salivary Lactobacilli. These results have shown that host protein containing 
chewing gum, Biotène
®
 has no additional benefits. However, chewing gums containing a 
substantial amount of xylitol (offering more than 6g/day) are beneficial in the prevention of 
dental plaque and hence dental caries. Xylitol containing chewing gums together with other 
oral hygiene products may provide additional benefits.   
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6   LIMITATIONS 
 The greatest limitation to this study was the small sample size. When the sample size 
is small, the statistical tests may have inadequate power to detect a particular effect. 
Our study population required healthy, young (18-23yrs old) individuals who had 
reduced saliva flow rates. However, after screening 109 students, only 18 met the 
criteria because although hyposalivation is present among young individuals, it is 
rare. Of these 18, only 13 agreed to participate in the study. 
 Another limitation was subject compliance. Although we asked students to bring back 
empty boxes of the treatment modalities, compliance was not guaranteed. 
Furthermore the diet of the students may have been very different in each phase of the 
study such as being more cariogenic during stressful periods such as exams.  Thus this 
lack of a standardised diet during all treatment modalities may have resulted in some 
inaccuracies. 
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7   APPENDICES 
APPENDIX A- Ethics clearance certificate granted by the Committee for Research on 
Human Subjects (Medical) 
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APPENDIX B- Consent form for subjects 
For verbal consent 
Good Day, 
How are you? 
I am Dr Thanusha Pillay a postgraduate student at University of The Witwatersrand.  In order 
to fulfil my M Sc dent degree requirements, I am conducting a research project on Biotène® 
chewing gum and dental caries susceptibility. Dental caries or tooth decay is a  major 
problem worldwide including South Africa. Secretion of saliva in our mouth protects us from 
caries. Some people have low saliva flow in their mouth which makes them vulnerable to 
caries. Many oral hygiene products are commercially available which improves saliva flow 
and oral health. Biotène® chewing gum is one of the products that can be used to improve 
saliva flow.  I would like to study the effect of Biotène® chewing gum on the production of 
saliva and oral health status. 
 
In order to do my study, I would like to measure your plaque index where you will rinse your 
mouth with a colour solution given to you which will stain plaque on your tooth and I will 
count the stained areas. This solution is perfectly safe to use and dentists use it on their 
patients regularly. You will be asked to collect saliva for 10 minutes at resting, 10 minutes 
while chewing rubber tubing given to you and 10 minutes while putting drops of diluted citric 
acid which is lemon juice on your tongue. You will be given toothpaste and a tooth brush to 
use while participating in this study. You will be asked to chew 5 pieces of Biotène® 
chewing gum a day for two weeks which will be given to you. After two weeks the plaque 
index and saliva test will be repeated. These tests will take 40 minutes of your time at the 
beginning and at the end of the study participation. I know as a student your time is precious, 
we can do these tests at your convenience such as lunch time or after hours. The samples will 
be processed in the laboratory. 
 
These tests will cause no harm to you. Whether you decide on participating or not, is entirely 
up to you.  Your decision will not affect you in any way.  If you agree to participate, you may 
withdraw from the study at any time without affecting you in any way.  If you wish, I will 
disclose the results to you and if required advise you on corrective measures. We all will 
benefit from the knowledge achieved from this study. 
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Your sample will be given a number and will be processed under a number. Your name will 
not appear anywhere on the results or on any publications. This study has been through 
University ethics committee. Should you have any problems please contact Prof P. Cleaton-
Jones at 011 717-1234  
Patient’s name:      Investigator’s name: 
Date:        Date: 
Signature:         Signature: 
         Tel. No: 082 705 8992 
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APPENDIX C- Flow diagram showing study design 
Subjects were screened for the saliva flow (109) 
 
Hyposalivating subjects were selected (13) 
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Buffering capacity - resting saliva 
Buffering capacity - stimulated saliva 
S. mutans & Lactobacilli count 
Plaque index 
 
Repeat tests (After) 
Flow - Resting saliva  
Flow - Stimulated saliva  
Buffering capacity - resting saliva 
Buffering capacity - stimulated saliva 
S. mutans & Lactobacilli count 
Plaque index 
 
Repeat tests (After) 
Flow - Resting saliva  
Flow - Stimulated saliva  
Buffering capacity - resting saliva 
Buffering capacity - stimulated saliva 
S. mutans & Lactobacilli count 
Plaque index 
 
Subjects were given 
Xylitol gum for 2 
weeks 
Subjects were given 
rubber tubing for 2 
weeks 
Subjects were given  
Biotène® gum for 2 
weeks 
Subjects recovered from 
the effect of Xylitol gum 
for 2 weeks 
Subjects recovered from 
the effect of rubber 
tubing for 2 weeks 
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